Danske Lægers Vaccinations Service

Research site

Denmark Gladsaxevej 376. 1., 2860 Søborg, Denmark

1 trial recruiting
COVID-19 · Respiratory syncytial virus infection · Herpes zoster
Adult patients

About Specializations

Danske Lægers Vaccinations Service in Søborg, Denmark specialises in clinical trials of conditions such as COVID-19, Respiratory syncytial virus infection, Herpes zoster, Influenza, and other specialisations. This site conducts important research.

Main research areas of the site

Virus Diseases – Respiratory Syncytial Virus

The site focuses on preventing severe RSV infection in adults. A pragmatic trial evaluates the Abrysvo vaccine for reducing hospitalizations.

Pragmatic randomized design
Assessment of hospitalization risk
Adults aged 18 years and older

Danske Lægers Vaccinations Service leads efforts to protect the adult population from serious respiratory disease outcomes.

Skin and Connective Tissue Diseases – Herpes Zoster

Research evaluates the impact of the recombinant shingles vaccine on cardiovascular health and cognitive decline. The study examines the Shingrix vaccine’s effect on major adverse cardiovascular events and new dementia cases.

Evaluation of cardiovascular outcomes
Investigation of dementia risk
Adults aged 65 years and older

This work highlights broader benefits of vaccination beyond infection control at Danske Lægers Vaccinations Service.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Gladsaxevej 376. 1.2860 SøborgDenmark

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 4

More sites in Søborg Denmark

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

5 clinical trials

COVID-19+1

Recruiting

Effectiveness of mCOMBRIAX vaccine compared with high‑dose influenza vaccine and mRNA‑1273 in adults ≥65 years for prevention of influenza and COVID‑19

Registered drugNo placebo

Effectiveness of mCOMBRIAX vaccine compared with high‑dose influenza vaccine and mRNA‑1273 in adults ≥65 years for prevention of influenza and COVID‑19

Registered drugNo placebo

Denmark

Participants:65+ years · Healthy volunteers
Substances:B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type)
Sponsor:Gentofte Hospital

Contact Research Centre

Respiratory syncytial virus infection

Not yet recruiting

Effectiveness of a second dose of RSV subgroup A 847A and subgroup B 847B versus primary dose to prevent respiratory syncytial virus infection in immunocompromised adults

Registered drugNo placebo

Effectiveness of a second dose of RSV subgroup A 847A and subgroup B 847B versus primary dose to prevent respiratory syncytial virus infection in immunocompromised adults

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A
Sponsor:Pfizer Inc.

Contact Research Centre

Herpes zoster

Not recruiting

Evaluating the effect of recombinant varicella zoster virus glycoprotein E vaccine on heart problems and dementia in adults aged 65 years or older with herpes zoster

Registered drugNo placebo

Evaluating the effect of recombinant varicella zoster virus glycoprotein E vaccine on heart problems and dementia in adults aged 65 years or older with herpes zoster

Registered drugNo placebo

Denmark

Participants:65+ years · Healthy volunteers
Substances:Recombinant Varicella Zoster Virus Glycoprotein E
Sponsor:Gentofte Hospital

Contact Research Centre

COVID-19

Not recruiting

A Study Testing mRNA-1273 Vaccine Safety and Effectiveness Against Severe COVID-19 in Adults Aged 50-64 Years Without Risk Factors

Registered drugNo placebo

A Study Testing mRNA-1273 Vaccine Safety and Effectiveness Against Severe COVID-19 in Adults Aged 50-64 Years Without Risk Factors

Registered drugNo placebo

Denmark

Participants:18–64 years · Healthy volunteers
Substances:Elasomeran
Sponsor:Gentofte Hospital

Contact Research Centre

Respiratory syncytial virus infection

Not recruiting

Study on the Effectiveness of RSV Vaccine (Abrysvo) in Preventing Hospitalizations in Adults Aged 60 and Older

Registered drugNo placebo

Study on the Effectiveness of RSV Vaccine (Abrysvo) in Preventing Hospitalizations in Adults Aged 60 and Older

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A
Sponsor:Gentofte Hospital

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites